ArcherDx, GenomOncology Ink Co-Marketing Agreement, Collaborate on NGS Workflow | GenomeWeb

NEW YORK (GenomeWeb) – ArcherDx and GenomOncology today announced an agreement to co-market ArcherDx's next-generation sequencing assays alongside GenomOncology's data interpretation software.

Under the terms of the agreement, GenomOncology's GO Clinical Workbench will support interpretation of several ArcherDx assays, including the ALK, RET, ROS1, Solid Tumor, and Comprehensive Thyroid and Lung panels.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

In Nature this week: genetic history of HIV in the US, and more.